- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss cost cutting with biosimilars.
As summer fades away and the United States prepares for a potential second wave of coronavirus disease 2019 (COVID-19) cases, many are worried that economic impacts and rising health care costs will continue unless action is taken. Europe’s competitive biosimilar market has proven that biosimilars have the potential to lower costs. But with existing barriers, such as lack of education and payer oversight of formularies, and the continuing pandemic, there is some debate on whether biosimilars will have the same impact in the United States.
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss how biosimilars can help curb costs in the time of COVID-19 and beyond.
To learn more about COVID-19's impact on biosimilars, click here.
To learn more about biosimilar education, click here.
To learn more about step therapy, click here.
To learn more about payer interference on preferred drugs, click here.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
